Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Dec 15;27(1):66.
doi: 10.1038/s41533-017-0066-2.

Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes

Lynda Doward  1 , Henrik Svedsater  2 , Diane Whalley  1 , Rebecca Crawford  1 , David Leather  3 , James Lay-Flurrie  4 , Nick Bosanquet  5
Affiliations
Randomized Controlled Trial

Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes

Lynda Doward et al. NPJ Prim Care Respir Med. .

Abstract

This study investigated patient perceptions, experiences and management of COPD throughout the SLS COPD study. Follow-up interviews were conducted with 400 patients who completed SLS COPD; a mixed-methods approach was used to collect quantitative and qualitative information. Structured interviews using closed-ended questions were conducted with 360 patients, detailing aspects of background/lifestyle information and COPD. Extended interviews containing open-ended questions on perceptions of COPD and quality of life (QoL) in addition to the closed-ended questions were completed by 40 further patients. Participants also completed the Adherence Starts with Knowledge-12 (ASK-12) and the COPD and Asthma Sleep Impact Scale (CASIS) questionnaire. Quantitative data were analysed descriptively; qualitative data were analysed using qualitative description. The participants (n = 400) were reasonably representative of the SLS COPD population; mean age was 66.2 years. Breathlessness was the most commonly recalled symptom of/associated with COPD (88.5% of patients) and was the symptom that changed the most (improved, 26.8%/worsened, 20.9%) throughout the study. Participants' daily functioning and activities were most affected by symptoms of/associated with COPD, followed by relationships and psychological issues. 66.5% of participants experienced exacerbations, 60.5% of whom reported self-management as their first treatment strategy (taking antibiotics, resting and/or corticosteroids). Qualitative analysis revealed COPD symptoms, breathlessness in particular, to have a significant impact on mobility and in turn QoL. In conclusion, breathlessness was cited in these interviews as the COPD symptom with the greatest impact on participants' daily functioning, activities and self-care. The findings provided significant additional knowledge to the SLS COPD study findings.

PubMed Disclaimer

Conflict of interest statement

L.D., D.W. and R.C. are employees of RTI Health Solutions, which has received funding from GSK. H.S., D.L. and J.L.-F. are GSK employees and hold GSK shares. N.B. was a chief investigator for the SLS follow-up interviews and received a fee from GSK.

Figures

Fig. 1
Fig. 1
Patient recruitment process and consent. EOS end-of-study, SLS COPD Salford Lung Study in patients with chronic obstructive pulmonary disease
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2017 report). http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-preve... (2017). - PubMed
    1. Svedsater, H. et al. Life impact and treatment preferences of individuals with asthma and chronic obstructive pulmonary disease: results from qualitative interviews and focus groups. Adv. Ther. 34, 1466–1481 (2017). - PMC - PubMed
    1. Halpin DM, Kerkhof M, Soriano JB, Mikkelsen H, Price DB. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir. Res. 2016;17:120. doi: 10.1186/s12931-016-0433-5. - DOI - PMC - PubMed
    1. Kruis AL, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9:e90145. doi: 10.1371/journal.pone.0090145. - DOI - PMC - PubMed
    1. Vestbo J, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N. Engl. J. Med. 2016;375:1253–1260. doi: 10.1056/NEJMoa1608033. - DOI - PubMed

Publication types